Catabasis Pharmaceuticals, Inc. (CATB) Stock Analysis

Catabasis Pharmaceuticals, Inc. (CATB) Healthcare & Pipeline Overview

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for rare diseases, primarily Duchenne muscular dystrophy (DMD) and cystic fibrosis. Their lead product, edasalonexent, is currently in Phase III clinical trials, positioning them in the competitive biotechnology landscape.

What Is the Investment Thesis for CATB?

Catabasis Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the potential approval and commercialization of edasalonexent for Duchenne muscular dystrophy (DMD). Positive Phase III clinical trial results and subsequent FDA approval could significantly increase the company's market capitalization. However, the company's current profit margin of -13938.2% highlights its reliance on future product revenue or further capital raises. The ongoing development of CAT-5571 for cystic fibrosis and tuberculosis represents a secondary growth catalyst, although these programs are in earlier stages of development. The company's beta of 1.66 indicates higher volatility compared to the overall market. The absence of a dividend reflects the company's focus on reinvesting capital into research and development. Success hinges on navigating regulatory hurdles, securing partnerships, and effectively commercializing its therapeutic candidates. Upcoming data readouts from clinical trials will be critical milestones.

Based on FMP financials and quantitative analysis

CATB Key Highlights

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on rare diseases.

• Lead product candidate, edasalonexent, is in Phase III clinical trials for Duchenne muscular dystrophy (DMD).
• Developing CAT-5571 for the treatment of cystic fibrosis and tuberculosis.
• Preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy.
• Agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis.

Who Are CATB's Competitors?

CATB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CATB's Key Strengths?

Lead product candidate in Phase III clinical trials.

• Focus on rare diseases with unmet medical needs.
• Collaborations with reputable research institutions.
• Experienced management team.

What Are CATB's Weaknesses?

Limited financial resources.

• Reliance on the success of a few key product candidates.
• High risk of clinical trial failure.
• Negative profit margin.

What Could Drive CATB Stock Higher?

Data readout from Phase III clinical trial of edasalonexent for DMD.

• Potential FDA submission for edasalonexent.
• Development of CAT-5571 for cystic fibrosis and tuberculosis.
• Expansion of research collaborations.

What Are the Key Risks for CATB?

Negative return on equity (-35.7%) — the business is not currently generating profit on shareholder capital.

• Unfavorable clinical trial results for edasalonexent.
• Regulatory delays or rejection of edasalonexent.
• Competition from other companies developing therapies for DMD and cystic fibrosis.
• Difficulty raising capital to fund research and development.
• Product liability risks associated with therapeutic development.

What Are the Growth Opportunities for CATB?

• Efficacy of Edasalonexent in DMD: The primary growth opportunity lies in the successful completion of Phase III clinical trials for edasalonexent in Duchenne muscular dystrophy (DMD). Positive results demonstrating significant clinical benefit could lead to FDA approval and subsequent commercialization. Timeline for potential FDA approval and launch is estimated within the next 2-3 years, pending trial outcomes and regulatory review. This would establish Catabasis as a key player in the DMD treatment landscape.
• Development of CAT-5571 for Cystic Fibrosis: The development of CAT-5571 for cystic fibrosis represents another significant growth opportunity. Cystic fibrosis is a genetic disorder affecting thousands of people worldwide, creating a substantial market for effective therapies. Positive preclinical and clinical data could attract partnerships or further investment in CAT-5571's development. The cystic fibrosis market is projected to grow, driven by advancements in treatment and increased patient access. The timeline for CAT-5571's potential commercialization is longer-term, likely 5+ years, given its earlier stage of development.
• Expansion into Dysferlinopathy: The preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy presents a potential expansion into a new therapeutic area. Dysferlinopathy is a rare genetic muscle disorder with limited treatment options, creating an unmet medical need. Positive preclinical results could lead to further clinical development and commercialization opportunities. The dysferlinopathy market is smaller than the DMD or cystic fibrosis markets, but represents a niche opportunity for Catabasis. This expansion could diversify Catabasis's pipeline and reduce its reliance on edasalonexent.
• Partnerships and Collaborations: Catabasis can pursue strategic partnerships and collaborations to accelerate the development and commercialization of its therapeutic candidates. Collaborations with larger pharmaceutical companies could provide access to funding, expertise, and distribution networks. The agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis demonstrates the potential for partnerships to expand the applications of Catabasis's therapies. These partnerships can de-risk development programs and enhance the company's overall growth prospects.
• Orphan Drug Designations and Regulatory Incentives: Obtaining orphan drug designations for its therapeutic candidates can provide Catabasis with regulatory incentives such as market exclusivity and tax credits. These incentives can reduce development costs and enhance the commercial attractiveness of its products. Orphan drug designations are available for therapies targeting rare diseases, aligning with Catabasis's focus on unmet medical needs. Successfully leveraging these regulatory pathways can accelerate the development and commercialization of its therapies.

What Are CATB's Competitive Advantages?

• Patented therapeutic candidates.
• Orphan drug designations providing market exclusivity.
• Clinical trial data demonstrating safety and efficacy.
• Collaborations with leading research institutions.

What Does CATB Do?

Founded in 2008 and based in Boston, Massachusetts, Catabasis Pharmaceuticals, Inc. is dedicated to discovering, developing, and commercializing innovative therapeutics. The company focuses on addressing unmet needs in rare diseases, with a primary emphasis on Duchenne muscular dystrophy (DMD) and cystic fibrosis. Their lead product candidate, edasalonexent, is an oral small molecule designed to inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), a key driver of inflammation and muscle degeneration in DMD. Edasalonexent is currently in Phase III clinical trials, representing a significant milestone in its development. In addition to edasalonexent, Catabasis is developing CAT-5571 for the treatment of cystic fibrosis. This compound aims to address the underlying causes of cystic fibrosis, offering a potential new therapeutic option for patients. The company also engages in collaborative research efforts, including a preclinical collaboration with the Jain Foundation to explore edasalonexent's potential in treating dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to investigate CAT-5571 in drug-sensitive and drug-resistant tuberculosis. These collaborations underscore Catabasis's commitment to expanding the applications of its therapeutic candidates and addressing global health challenges. Catabasis operates primarily in the United States, focusing on clinical development and potential commercialization of its rare disease therapies.

What Products and Services Does CATB Offer?

• Develop therapeutics for rare diseases.
• Focus on Duchenne muscular dystrophy (DMD) and cystic fibrosis.
• Conduct Phase III clinical trials for edasalonexent in DMD.
• Develop CAT-5571 for the treatment of cystic fibrosis and tuberculosis.
• Engage in preclinical research collaborations.
• Seek regulatory approval for its therapeutic candidates.
• Commercialize approved therapies in the United States.

How Does CATB Make Money?

• Develop and patent novel therapeutics.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA.
• Commercialize approved therapies directly or through partnerships.

What Industry Does CATB Operate In?

Catabasis Pharmaceuticals, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The market for rare disease treatments is growing, driven by increased awareness, improved diagnostic capabilities, and regulatory incentives such as orphan drug designation. Catabasis's focus on Duchenne muscular dystrophy (DMD) and cystic fibrosis places it in direct competition with other companies developing therapies for these conditions. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.

Who Are CATB's Key Customers?

• Patients with Duchenne muscular dystrophy (DMD).
• Patients with cystic fibrosis.
• Healthcare providers who treat these patients.
• Pharmaceutical companies seeking to partner or acquire novel therapies.

Company Profile

Catabasis Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Jill Milne. CATB has traded publicly since 2015.

How Catabasis Pharmaceuticals, Inc. Is Valued

Catabasis Pharmaceuticals, Inc. carries a market capitalization of $235M, placing it in the micro-cap category.

Return on equity for Catabasis Pharmaceuticals, Inc. stands at -35.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -43.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.78 indicates the company holds enough short-term assets to cover its near-term obligations.

The most recent 12 insider filings for Catabasis Pharmaceuticals, Inc. break down as 0 sales and 12 purchases. On net that is roughly 3.1M shares acquired (about $8.3M) — insiders putting money in tends to read as conviction.

CATB Financials

CATB Latest News

CATB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources